{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"5.8","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.\n\nbortezomib thalidomide","id":"OG000","title":"Bortezomib and Thalidomide"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"1-6 months","title":"The Time to Response","type":"SECONDARY","unitOfMeasure":"months"}